Eli Lilly's Oral GLP-1 Associated With Reduced Risk of Type 2 Diabetes, Heart Disease in Adults With Obesity
By Kelly Cloonan
Eli Lilly's oral GLP-1 drug Foundayo was associated with a lower predicted long-term risk of both type 2 diabetes and heart disease in adults with obesity, according to a recent analysis.
The company said Thursday that the results suggest Foundayo could help reduce long-term spending for patients and healthcare systems.
The analysis found that patients taking 5.5 milligram, 9 milligram and 17.2 milligram doses of Foundayo showed an estimated 45%, 50% and 57% reduction, respectively, in predicted type 2 diabetes risk versus placebo at 72 weeks.
Participants taking the 17.2 milligram dose of Foundayo also showed an estimated 18% reduction in predicted cardiovascular disease risk versus placebo, the company said.
The analysis was based on a Phase 3, 72-week trial comparing the three doses of Foundayo to placebo in adults with obesity, or overweight with a weight-related medical problem.
Lilly said the results show Foundayo could help lower healthcare costs by both treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
October 01, 2026 08:05 ET (12:05 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States